Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Cottu P, Ring A, Abdel-Razeq H, Marchetti P, Cardoso F, Salvador Bofill J, Martín M, Menon-Singh L, Wu J, De Laurentiis M. Cottu P, et al. Breast. 2022 Apr;62:75-83. doi: 10.1016/j.breast.2022.01.016. Epub 2022 Jan 31. Breast. 2022. PMID: 35131646 Free PMC article. Clinical Trial.
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Im YH, Karabulut B, Lee KS, Park BW, Adhav A, Cinkir HY, Abdel-Razeq H, Chang YC, Aksoy S, Im SA, Jeong J, Chae Y, Bowles J, Slimane K, Xue H, Kim SB. Im YH, et al. Breast Cancer Res Treat. 2021 Jul;188(1):77-89. doi: 10.1007/s10549-021-06173-z. Epub 2021 Mar 16. Breast Cancer Res Treat. 2021. PMID: 33728524
Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.
Abdel-Razeq H, Sharaf B, AlMasri R, Abdel-Razeq R, Tamimi F, Khader O, Salama O, Abunasser M, Edaily S, Abdulelah H. Abdel-Razeq H, et al. Cancer Manag Res. 2022 Mar 8;14:1033-1041. doi: 10.2147/CMAR.S353584. eCollection 2022. Cancer Manag Res. 2022. PMID: 35300061 Free PMC article.
Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib.
Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H. Sharaf B, et al. Breast Cancer (Dove Med Press). 2023 Jul 28;15:541-548. doi: 10.2147/BCTT.S415432. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 37533590 Free PMC article.
129 results